Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer Holdings Corporation (NYSE:ITGR) reported second-quarter 2020 results, posting a 24% decline in sales to $240 million compared to the same quarter last year, attributed to the COVID-19 pandemic. GAAP income plummeted 99% to $0.4 million, while non-GAAP adjusted income fell 74% to $10 million. Despite the challenges, the company maintained ample liquidity and reduced total debt by $33 million to $770 million. Notable was the affirmation of a $27 million patent infringement ruling in its favor. Integer continues to adapt strategically to shifting demands.
Integer Holdings Corporation (NYSE: ITGR) will announce its Q2 2020 financial and operational results on July 30, 2020, at 8 a.m. ET. A webcast led by Integer management will follow at 9 a.m. ET. The call will cover forward-looking information and material updates. Investors can join via phone or through the Investor Relations section of Integer's website. Integer is a leading medical device manufacturer serving diverse markets, including cardiac and neuromodulation.
Integer Holdings Corporation (NYSE: ITGR) has achieved a significant legal victory as the U.S. Court of Appeals for the Federal Circuit confirmed a judgment of over $27M in its favor against AVX Corporation. This ruling comes after a lengthy patent infringement case initiated in 2013, where Integer's subsidiary, Greatbatch Ltd., accused AVX of infringing three patents related to vital medical device components for pacemakers and defibrillators. Senior VP, Elizabeth Giddens, expressed satisfaction with the outcome, marking it as a complete victory for the company.
Integer Holdings Corporation (NYSE: ITGR) announced a successful amendment to its senior secured credit facility amid the COVID-19 pandemic. This precautionary measure aims to enhance liquidity and support ongoing strategic investments and acquisitions. The amendment adjusts the covenant net leverage ratio from 4.00 to 1.00 to 4.75 to 1.00 for the period from Q3 2020 to Q2 2021, before stepping down to 4.50 to 1.00 for one quarter. The company will incur advanced and deferred amendment fees to consenting lenders as part of this arrangement, showcasing strong lender support.
Integer Holdings Corporation (NYSE: ITGR) has opened a new Galway Research and Development (R&D) Innovation Centre in Ireland. This 8,500 square foot facility will enhance Integer's ability to develop high-quality medical devices, particularly in the cardio and vascular sectors. With increased lab space and collaborative environments, the center will support innovation and growth for Integer and its customers. The Galway facility complements existing operations and aims to strengthen Integer's position within the global medical device sector.
Integer Holdings Corporation (NYSE:ITGR) announced its financial results for Q1 2020, reporting a 45% increase in GAAP EPS and a 26% rise in adjusted income. Total sales grew 4% to $328 million. Despite challenges from COVID-19, sales were largely unaffected, particularly in Cardio & Vascular, which rose 17%. However, the company suspended its annual guidance due to uncertainties surrounding the pandemic. A total debt reduction to $804 million was noted, achieving a leverage ratio of 2.8 times adjusted EBITDA.